Anti-viral compositions

Details Anti-viral compositions Anti-viral compositions

1995-01-09

1997-10-07

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 15, 514 16, 530327, 530328, 530329, A61K 3808

Patent

active

056748493

ABSTRACT:
An anti-viral composition includes a synergistic combination of an anti-viral nucleoside analogue, which may inhibit a virus-specific enzyme, such as viral thymidine kinase and reverse transcriptase, an anti-viral oligonucleotide compound having from 6 to 12 amino acid residues substantially all of which are D-arginine residues, and a pharmaceutically acceptable carrier. A method for treating a viral infection is also described.

REFERENCES:
patent: 4042330 (1977-08-01), Deshmukh
patent: 4252784 (1981-02-01), Levine
patent: 4447356 (1984-05-01), Olivera
patent: 4713366 (1987-12-01), Stevens
patent: 4837304 (1989-06-01), Garsky et al.
patent: 4845195 (1989-07-01), Colonno et al.
patent: 5021437 (1991-06-01), Blumenkopf
patent: 5093317 (1992-03-01), Lewis
patent: 5110799 (1992-05-01), Tolman
patent: 5110802 (1992-05-01), Cantin et al.
patent: 5114711 (1992-05-01), Bell
patent: 5166320 (1992-11-01), Wu et al.
patent: 5171838 (1992-12-01), Chiba
patent: 5175165 (1992-12-01), Blumenkopf
Docherty Antimicrob Agents Chemother. 31, 1562, 1987.
Coy Bioch Biophys Res Comm 73 632, 1976.
Weeks, Science 249, 1281, 1990.
Elion, "Mechanism of Action and Selectivity of Acyclovir," The American Journal of Medicine, vol. 73, No. 1A, pp. 7-13 (1982).
Ratner et al., "Complete Nucleotide Sequence of the AIDS Virus, HTLV-III," Nature, vol. 313, pp. 277-284, (Jan. 1985).
Nahata, "Antiviral Drugs: Pharmacoknetics, Adverse Effects, and Therapeutic Use," Journal of Pharmacy Technology, vol. 3, pp. 100-108 (May/Jun. 1987).
Green et al., "Autonomous Functional Domains of Chemically Synthesized Human Immunodeficiency Virus Tat Trans-Activator," Cell, vol. 55, pp. 1179-1188 (Dec. 1988).
Ruben et al., "Structural and Functional Characterization of Human Immunodeficiency Virus tat Protein," vol. 63, No. 1, pp. 1-8 (Jan. 1989).
Hauber et al., "Mutational Analysis of the Conserved Basic Domain of Human Immunodeficiency Virus tat Protein," Journal of Virology, vol. 63, No. 3, pp. 1181-1187 (Mar. 1989).
Green et al., "Mutational Analysis of HIV-1 Tat Minimal Domain Peptides: Identification of Trans-Dominant Mutants That Suppress HIV-LTR-Driven Gene Expression," Cell, vol. 58, pp.215-223 (Jul. 1989).
M. Kuppuswamy et al., "Multiple Functional Domains of Tat, the trans-activator of HIV-1, Defined by Mutational Analysis," Nucleic Acids Research, vol. 17, No. 9, pp. 3551-3561 (1989).
Frankel et al., "Activity of Synthetic Peptides from the Tat Protein of Human Immunodeficiency Virus Type 1," Proc. Nat'l. Acad. Sci. USA, vol. 86, pp. 7397-7401 (Oct. 1989).
Arnold, Jr., "Polylysin-Drug Conjugates," Methods in Enzymology, vol. 112, pp. 270-285 (1985).
Weeks et al., "Fragments of the HIV-1 Tat Protein Specifically Bind TAR RNA," Science, vol. 249, pp. 1281-1285 (1990).
Roy et al., "A Bulge Structure in HIV-1 TAR RNA is Required for Tat Binding and Tat-Mediated trans-Activation," Genes and Development, vol. 4, pp. 1365-1373 (1990).

Affiliated with

Also associated with

Rating

Anti-viral compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-viral compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-viral compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2357438